A Novel Strategy for Pharmaceutical Cocrystal Generation Without Knowledge of Stoichiometric Ratio: Myricetin Cocrystals and a Ternary Phase Diagram
详细信息 查看全文
- 作者：Chao Hong (1)
Yan Xie (1)
Yashu Yao (1) (3)
Guowen Li (2)
Xiurong Yuan (1)
Hongyi Shen (1)
1. Research Center for Health and Nutrition ; Shanghai University of Traditional Chinese Medicine ; Shanghai ; 201203 ; China
3. Institute of Chinese Materia Medica ; Shanghai University of Traditional Chinese Medicine ; Shanghai ; 201203 ; China
2. Pharmacy Department ; Shanghai TCM-Integrated Hospital ; Shanghai ; 200082 ; China - 关键词：dissolution ; myricetin ; pharmaceutical cocrystals ; preparation ; ternary phase diagram
- 刊名：Pharmaceutical Research
- 出版年：2015
- 出版时间：January 2015
- 年：2015
- 卷：32
- 期：1
- 页码：47-60
- 全文大小：2,289 KB
- 参考文献：1. Eddleston MD, Sivachelvam S, Jones W. Screening for polymorphs of cocrystals: a case study. Cryst Eng Comm. 2013;15(1):175鈥?1. 2ce26496j" target="_blank" title="It opens in new window">CrossRef
2. Qiao N, Li MZ, Schlindwein W, Malek N, Davies A, Trappitt G. Pharmaceutical cocrystals: an overview. Int J Pharm. 2011;419(1鈥?):1鈥?1. 2011.07.037" target="_blank" title="It opens in new window">CrossRef
3. Seliger J, Zagar V. Nuclear quadrupole resonance characterization of carbamazepine cocrystals. Solid State Nucl Magn Reson. 2012;47鈥?8(1):47鈥?2. 2012.09.001" target="_blank" title="It opens in new window">CrossRef
4. Yamamoto K, Tsutsumi S, Ikeda Y. Establishment of cocrystal cocktail grinding method for rational screening of pharmaceutical cocrystals. Int J Pharm. 2012;437(1鈥?):162鈥?1. 2012.07.038" target="_blank" title="It opens in new window">CrossRef
5. Lipinski CA. Drug-like properties and the causes of poor solubility and poor permeability. J Pharmacol Toxicol Methods. 2000;44(1):235鈥?9. CrossRef
6. Ong KC, Khoo HE. Biological effects of myricetin. Gen Pharmacol Vasc Sys. 1997;29(2):121鈥?. 23(96)00421-1" target="_blank" title="It opens in new window">CrossRef
7. Scheidt HA, Pampel A, Nissler L, Gebhardt R, Huster D. Investigation of the membrane localization and distribution of flavonoids by high-resolution magic angle spinning NMR spectroscopy. Biochim Biophys Acta. 2004;1663(1鈥?):97鈥?07. 2004.02.004" target="_blank" title="It opens in new window">CrossRef
8. Kim H, Choi J, Jung S. Inclusion complexes of modified cyclodextrins with some flavonols. J Incl Phenom Macrocycl Chem. 2009;64(1鈥?):43鈥?. CrossRef
9. Mira L, Fernandez MT, Santos M, Rocha R, Florencio MH, Jennings KR. Interactions of flavonoids with iron and copper ions: a mechanism for their antioxidant activity. Free Radic Res. 2002;36(11):1199鈥?08. 21000016463" target="_blank" title="It opens in new window">CrossRef
10. Roedig-Penman A, Gordon MH. Antioxidant properties of myricetin and quercetin in oil and emulsions. J Am Oil Chem Soc. 1998;75(2):169鈥?0. 29-4" target="_blank" title="It opens in new window">CrossRef
11. Ma ZG, Liu TW. Myricetin facilitates potassium currents and inhibits neuronal activity of PVN neurons. Neurochem Res. 2012;37(7):1450鈥?. 2-0732-2" target="_blank" title="It opens in new window">CrossRef
12. Yao YS, Lin GB, Xie Y, Ma P, Li GW, Meng QC, / et al. Preformulation studies of myricetin: a natural antioxidant flavonoid. Die Pharm. 2014;69(1):19鈥?6.
13. Variankaval N, Wenslow R, Murry J, Hartman R, Helmy R, Kwong E, / et al. Preparation and solid-state characterization of nonstoichiometric cocrystals off a phosphodiesterase-IV inhibitor annul L-tartaric acid. Cryst Growth Des. 2006;6(3):690鈥?00. 21/cg050462u" target="_blank" title="It opens in new window">CrossRef
14. Leung DH, Lohani S, Ball RG, Canfield N, Wang YL, Rhodes T, / et al. Two novel pharmaceutical cocrystals of a development compound鈥搒creening, scale-up, and characterization. Cryst Growth Des. 2012;12(3):1254鈥?2. 21/cg201270s" target="_blank" title="It opens in new window">CrossRef
15. Arenas-Garcia JI, Herrera-Ruiz D, Mondragon-Vasquez K, Morales-Rojas H, Hopfl H. Modification of the supramolecular hydrogen-bonding patterns of acetazolamide in the presence of different cocrystal formers: 3:1, 2:1, 1:1, and 1:2 cocrystals from screening with the structural isomers of hydroxybenzoic acids, aminobenzoic acids, hydroxybenzamides, aminobenzamides, nicotinic acids, nicotinamides, and 2,3-dihydroxybenzoic acids. Cryst Growth Des. 2012;12(2):811鈥?4. 21/cg201140g" target="_blank" title="It opens in new window">CrossRef
16. Ando S, Kikuchi J, Fujimura Y, Ida Y, Higashi K, Moribe K, / et al. Physicochemical characterization and structural evaluation of a specific 2:1 cocrystal of naproxen-nicotinamide. J Pharm Sci. 2012;101(9):3214鈥?1. 2/jps.23158" target="_blank" title="It opens in new window">CrossRef
17. Gangopadhyay P, Radhakrishnan TP. Visualizing supramolecular macrocyclic formations. Mol Cryst Liq Cryst. 2001;369(1):167鈥?19. 250108030019" target="_blank" title="It opens in new window">CrossRef
18. Yenikaya C, Ogretir C. A quantum chemical study on structure of cocrystal of triphenylphosphine oxide and hydroquinone. J Mol Struct THEOCHEM. 2005;731(1鈥?):1鈥?. 2004.09.063" target="_blank" title="It opens in new window">CrossRef
19. Jayasankar A, Reddy LS, Bethune SJ, Rodriguez-Hornedo N. Role of cocrystal and solution chemistry on the formation and stability of cocrystals with different stoichiometry. Cryst Growth Des. 2009;9(2):889鈥?7. 21/cg800632r" target="_blank" title="It opens in new window">CrossRef
20. Chiarella RA, Davey RJ, Peterson ML. Making co-crystals鈥搕he utility of ternary phase diagrams. Cryst Growth Des. 2007;7(7):1223鈥?. 21/cg070218y" target="_blank" title="It opens in new window">CrossRef
21. Rodriguez-Hornedo N, Nehru SJ, Seefeldt KF, Pagan-Torres Y, Falkiewicz C. Reaction crystallization of pharmaceutical molecular complexes. Mol Pharm. 2006;3(3):362鈥?. 21/mp050099m" target="_blank" title="It opens in new window">CrossRef
22. Good DJ, Rodriguez-Hornedo N. Cocrystal eutectic constants and prediction of solubility behavior. Cryst Growth Des. 2010;10(3):1028鈥?2. 21/cg901232h" target="_blank" title="It opens in new window">CrossRef
23. Nehm SJ, Rodriguez-Spong B, Rodriguez-Hornedo N. Phase solubility diagrams of cocrystals are explained by solubility product and solution complexation. Cryst Growth Des. 2006;6(2):592鈥?00. 21/cg0503346" target="_blank" title="It opens in new window">CrossRef
24. Zhang S, Rasmuson AC. Thermodynamics and crystallization of the theophylline-glutaric acid cocrystal. Cryst Growth Des. 2013;13(3):1153鈥?1. 21/cg3014859" target="_blank" title="It opens in new window">CrossRef
25. Grossjohann C, Eccles KS, Maguire AR, Lawrence SE, Tajber L, Corrigan OI, / et al. Characterisation, solubility and intrinsic dissolution behaviour of benzamide: dibenzyl sulfoxide cocrystal. Int J Pharm. 2012;422(1鈥?):24鈥?2. 2011.10.016" target="_blank" title="It opens in new window">CrossRef
26. Childs SL, Rodriguez-Hornedo N, Reddy LS, Jayasankar A, Maheshwari C, McCausland L, / et al. Screening strategies based on solubility and solution composition generate pharmaceutically acceptable cocrystals of carbamazepine. Cryst Eng Comm. 2008;10(7):856鈥?4. CrossRef
27. Ainouz A, Authelin JR, Billot P, Lieberman H. Modeling and prediction of cocrystal phase diagrams. Int J Pharm. 2009;374(1鈥?):82鈥?. 2009.03.016" target="_blank" title="It opens in new window">CrossRef
28. Croker DM, Foreman ME, Hogan BN, Maguire NM, Elcoate CJ, Hodnett BK, / et al. Understanding the p-toluenesulfonamide/triphenylphosphine oxide crystal chemistry: a new 1:1 cocrystal and ternary phase diagram. Cryst Growth Des. 2012;12(2):869鈥?5. 21/cg201300e" target="_blank" title="It opens in new window">CrossRef
29. Seaton CC, Parkin A, Wilson CC, Blagden N. Controlling the formation of benzoic acid: isonicotinamide molecular complexes. Cryst Growth Des. 2009;9(1):47鈥?6. 21/cg701024c" target="_blank" title="It opens in new window">CrossRef
30. Eddleston MD, Lloyd GO, Jones W. Cocrystal dissociation and molecular demixing in the solid state. Chem Commun. 2012;48(65):8075鈥?. 2cc33412g" target="_blank" title="It opens in new window">CrossRef
31. Vangala VR, Chow PS, Tan RBH. Co-crystals and co-crystal hydrates of the antibiotic nitrofurantoin: structural studies and physicochemical properties. Cryst Growth Des. 2012;12(12):5925鈥?8. 21/cg300887p" target="_blank" title="It opens in new window">CrossRef
32. Schultheiss N, Newman A. Pharmaceutical cocrystals and their physicochemical properties. Cryst Growth Des. 2009;9(6):2950鈥?7. 21/cg900129f" target="_blank" title="It opens in new window">CrossRef
33. Stanton MK, Bak A. Physicochemical properties of pharmaceutical co-crystals: a case study of ten AMG 517 co-crystals. Cryst Growth Des. 2008;8(10):3856鈥?2. 21/cg800173d" target="_blank" title="It opens in new window">CrossRef
34. Weyna DR, Shattock T, Vishweshwar P, Zaworotko MJ. Synthesis and structural characterization of cocrystals and pharmaceutical cocrystals: mechanochemistry vs. slow evaporation from solution. Cryst Growth Des. 2009;9(2):1106鈥?3. 21/cg800936d" target="_blank" title="It opens in new window">CrossRef
35. Espinosa-Lara JC, Guzman-Villanueva D, Arenas-Garcia JI, Herrera-Ruiz D, Rivera-Islas J, Roman-Bravo P, / et al. Cocrystals of active pharmaceutical ingredients-praziquantel in combination with oxalic, malonic, succinic, maleic, fumaric, glutaric, adipic, and pimelic acids. Cryst Growth Des. 2013;13(1):169鈥?5. 21/cg301314w" target="_blank" title="It opens in new window">CrossRef
36. Mohamed S, Tocher DA, Price SL. Computational prediction of salt and cocrystal structures-does a proton position matter? Int J Pharm. 2011;418(2):187鈥?8. 2011.03.063" target="_blank" title="It opens in new window">CrossRef
37. Alhalaweh A, George S, Basavoju S, Childs SL, Rizvi SAA, Velaga SP. Pharmaceutical cocrystals of nitrofurantoin: screening, characterization and crystal structure analysis. Cryst Eng Comm. 2012;14(15):5078鈥?8. 2ce06602e" target="_blank" title="It opens in new window">CrossRef
38. Guo K, Sadiq G, Seaton C, Davey R, Yin QX. Co-crystallization in the caffeine/maleic acid system: lessons from phase equilibria. Cryst Growth Des. 2010;10(1):268鈥?3. 21/cg900885n" target="_blank" title="It opens in new window">CrossRef
39. Yamashita H, Hirakura Y, Yuda M, Teramura T, Terada K. Detection of cocrystal formation based on binary phase. Pharm Res. 2013;30(1):70鈥?0. 2-0850-1" target="_blank" title="It opens in new window">CrossRef
40. Thakuria R, Delori A, Jones W, Lipert MP, Roy L, Rodriguez-Hornedo N. Pharmaceutical cocrystals and poorly soluble drugs. Int J Pharm. 2013;453(1):101鈥?5. 2012.10.043" target="_blank" title="It opens in new window">CrossRef
41. Bethune SJ, Huang N, Jayasankar A, Rodriguez-Hornedo N. Understanding and predicting the effect of cocrystal components and pH on cocrystal solubility. Cryst Growth Des. 2009;9(9):3976鈥?8. 21/cg9001187" target="_blank" title="It opens in new window">CrossRef
42. Alhalaweh A, Roy L, Rodriguez-Hornedo N, Velaga SP. pH-dependent solubility of indomethacin-saccharin and carbamazepine-saccharin cocrystals in aqueous media. Mol Pharm. 2012;9(9):2605鈥?2. 21/mp300189b" target="_blank" title="It opens in new window">CrossRef
43. Reddy LS, Bethune SJ, Kampf JW, Rodriguez-Hornedo N. Cocrystals and salts of gabapentin: pH dependent cocrystal stability and solubility. Cryst Growth Des. 2009;9(1):378鈥?5. 21/cg800587y" target="_blank" title="It opens in new window">CrossRef
44. Gao YA, Zu H, Zhang JJ. Enhanced dissolution and stability of adefovir dipivoxil by cocrystal formation. J Pharm Pharmacol. 2011;63(4):483鈥?0. 2042-7158.2010.01246.x" target="_blank" title="It opens in new window">CrossRef
45. Rahman Z, Samy R, Sayeed VA, Khan MA. Physicochemical and mechanical properties of carbamazepine cocrystals with saccharin. Pharm Dev Technol. 2012;17(4):457鈥?5. 2010.546412" target="_blank" title="It opens in new window">CrossRef
46. Bruni G, Maietta M, Maggi L, Mustarelli P, Ferrara C, Berbenni V, / et al. Preparation and physicochemical characterization of acyclovir cocrystals with improved dissolution properties. J Pharm Sci. 2013;102(11):4079鈥?6. 2/jps.23721" target="_blank" title="It opens in new window">CrossRef
47. Bolla G, Sanphui P, Nangia A. Solubility advantage of tenoxicam phenolic cocrystals compared to salts. Cryst Growth Des. 2013;13(5):1988鈥?003. 21/cg4000457" target="_blank" title="It opens in new window">CrossRef
48. Maddileti D, Jayabun SK, Nangia A. Soluble cocrystals of the xanthine oxidase inhibitor febuxostat. Cryst Growth Des. 2013;13(7):3188鈥?6. 21/cg400583z" target="_blank" title="It opens in new window">CrossRef
49. Luo YH, Sun BW. Pharmaceutical co-crystals of pyrazinecarboxamide (PZA) with various carboxylic acids: crystallography, hirshfeld surfaces, and dissolution study. Cryst Growth Des. 2013;13(5):2098鈥?06. 21/cg400167w" target="_blank" title="It opens in new window">CrossRef
50. Shiraki K, Takata N, Takano R, Hayashi Y, Terada K. Dissolution improvement and the mechanism of the improvement from cocrystallization of poorly water-soluble compounds. Pharm Res. 2008;25(11):2581鈥?2. 2" target="_blank" title="It opens in new window">CrossRef
51. Childs SL, Kandi P, Lingireddy SR. Formulation of a danazol cocrystal with controlled supersaturation plays an essential role in improving bioavailability. Mol Pharm. 2013;10(8):3112鈥?7. 21/mp400176y" target="_blank" title="It opens in new window">CrossRef - 刊物类别：Biomedical and Life Sciences
- 刊物主题：Biomedicine
Pharmacology and Toxicology
Pharmacy
Biochemistry
Medical Law
Biomedical Engineering - 出版者：Springer Netherlands
- ISSN：1573-904X
文摘
Purpose To develop a streamlined strategy for pharmaceutical cocrystal preparation without knowledge of the stoichiometric ratio by preparing and characterizing the cocrystals of myricetin (MYR) with four cocrystal coformers (CCF). Methods An approach based on the phase solubility diagram (PSD) was used for MYR cocrystals preparation and the solid-state properties were characterized by differential scanning calorimetry (DSC), fourier transform-infrared spectroscopy (FT-IR), powder X-ray diffraction (PXRD), and scanning electron microscopy (SEM). The ternary phase diagram (TPD) was constructed by combining the PSD and nuclear magnetic resonance (NMR) data. After that, the TPD was verified by traditional methods. The dissolution of MYR in the four cocrystals and pure MYR within three different media were also evaluated. Results A simple research method for MYR cocrystal preparation was obtained as follows: first, the PSD of MYR and CCF was constructed and analyzed; second, by transforming the curve in the PSD to a TPD, a region of pure cocrystals formation was exhibited, and then MYR cocrystals were prepared and identified by DSC, FT-IR, PXRD, and SEM; third, with the composition of the prepared cocrystal from NMR, the TPD of the MYR-CCF-Solvent system was constructed. The powder dissolution data showed that the solubility and dissolution rate of MYR was significantly enhanced by the cocrystals. Conclusions A novel strategy for pharmaceutical cocrystals preparation without knowledge of the stoichiometric ratio based on the TPD was established and MYR cocrystals were successfully prepared. The present study provides a systematic approach for pharmaceutical cocrystal generation, which benefits the development and application of cocrystal technology in drug delivery.